Skip to main content

Table 1 Baseline characteristics and instrument scores of study participants

From: Early evidence of efficacy for orally administered SPM-enriched marine lipid fraction on quality of life and pain in a sample of adults with chronic pain

Characteristic (n = 44) Mean (n%)
Age (years) 45.5 (13.3)
Gender
 Female 31 (70.5)
 Male 12 (27.3)
 Transgender 1 (2.3)
Currently taking omega-3, fish oil or krill oil
 Yes 14 (31.8)
 No 30 (68.2)
Ethnicity
 Hispanic or Latino 3 (6.8)
 Not Hispanic or Latino 37 (84.1)
 Unknown/not reported 4 (9.1)
Race
 African American 1 (2.3)
 Caucasian 34 (77.3)
 African American and Caucasian 1 (2.3)
 Caucasian and Native American 2 (4.5)
 Asian and Pacific Islander 1 (2.3)
 Multi-racial (not specified) 2 (4.5)
 Unknown/not reported 3 (6.8)
Instrument scores (n = 44) Mean (SD)
Primary outcome measures
 ACPA QOL scale 6.8 (0.3)
 PROMIS-43 QOL subdomains
  Ability to participate in social roles and activities 45.5 (1.3)
  Fatigue 54.3 (1.5)
  Sleep disturbance 53.8 (1.2)
Exploratory outcome measures
 PHQ-9 7.3 (0.81)
 PROMIS-43, depression subdomain 52.2 (1.31)
 GAD-7 6.3 (0.66)
 PROMIS-43, anxiety subdomain 56.9 (1.36)
 BPI, pain intensity items
  Pain now 4.8 (0.28)
  Average pain 5.3 (0.18)
  Worst pain 6.7 (0.18)
  Least pain 3.3 (0.28)
 PROMIS-43, pain intensity subdomain 5.7 (0.19)
 BPI, pain interference 5.0 (0.36)
 PROMIS-43, pain interference subdomain 61.2 (0.95)
 PROMIS-43, physical function subdomain 41.3 (1.03)
 BPI, pain relief item 3.8 (0.36)
 hs-CRP 0.08 (0.19)
 ESR 5.18 (0.81)